Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Vaccines and Diagnostics has received the FDA's approval for its Ixiaro vaccine for the prevention of Japanese encephalitis. The vaccine will be marketed in the US as Ixiaro by Novartis Vaccines.
Subscribe to our email newsletter
Ixiaro was developed to provide a well-tolerated, effective and convenient vaccine against Japanese encephalitis (JE), suitable for administration to travelers who wish to reduce their risk of acquiring the disease, the company said.
Ixiaro was developed by Intercell. Novartis and Intercell have a strategic alliance based on a shared vision of science in vaccines R&D. The alliance provides Novartis with the development and commercialization rights to Intercell’s entire non-partnered early state vaccines pipeline.
Andrin Oswald, CEO of Novartis Vaccines and Diagnostics, said: “Asia is now the second most popular travel destination globally, and travel to the region is expected to increase. JE is spread by mosquitoes, which makes it unpredictable. Vaccination is the most effective preventive measure against the disease.”